Пресс-релизы
Oct
- Teva and Dr. Reddy’s announce launch of generic Zyprexa® in the United States
- Dr. Reddy’s Q2 FY12 Financial Results : Q2 FY12 Revenues at₹22.7 billion ($462 million)
- Dr. Reddy’s Q2 FY12 Financial Results : Q2 FY12 Revenues at₹22.7 billion ($462 million)
- Dr. Reddy's to release Q2 FY12 results on October 25, 2011 Earnings call slated for October 25, 6.30 PM IST / 9.00 AM EST
Sep
Aug
Jul
- FUJIFILM and Dr. Reddy’s to establish an exclusive joint venture for developing, manufacturing and promoting generic drugs in Japan
- Dr. Reddy’s announces the launch of Gemcitabine for Injection
- Dr. Reddy’s acquires prescription business of JB Chemicals & Pharmaceuticals in Russia & other CIS markets
- Dr. Reddy’s Q1 FY12 Financial Results:Q1 FY12 Revenues at₹19.7 billion ($444 million), YoY growth of 18%
- Dr. Reddy’s Q1 FY12 Financial Results:Q1 FY12 Revenues at₹19.7 billion ($444 million), YoY growth of 18%
- Dr. Reddy’s announces the USFDA Approval of Fondaparinux Sodium Injection
- Dr. Reddy's to release Q1 FY12 results on July 20, 2011 Earnings call slated for July 20, 6.30 PM IST / 9.00 AM EST
- Dr. Reddy’s announces the launch of Amlodipine Besylate and Benazepril Hydrochloride capsules
Jun
May
Apr
- Dr. Reddy's to release Q4 & Full Year FY11 results on May 13, 2011 Earnings call slated for May 13, 6.30 PM IST / 9.00 AM EST
- Dr. Reddy’s announces the launch of Over-the-Counter fexofenadine HCl tablets
- Dr. Reddy’s expands its R&D centre in Cambridge, United Kingdom
- PromiusTM Pharma and Valeant form collaboration to market Cloderm® cream in the United States
Mar
Jan
- Dr. Reddy’s provides update on the fexofenadine-pseudoephedrine 24 hour litigation
- Dr. Reddy’s Q3 FY11 Financial Results:Revenues at$19.0 billion ($424 million), YoY growth of 10%
- Dr. Reddy’s announces the launch of Pantoprazole Sodium delayed-released tablets
- Dr. Reddy's to release Q3 FY11 results on January 25, 2011 Earnings call slated for January 25, 6:30 PM IST / 8.00 AM EST
